205 related articles for article (PubMed ID: 3190993)
1. Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.
Day RO; Miners J; Birkett DJ; Graham GG; Whitehead A
Br J Clin Pharmacol; 1988 Oct; 26(4):429-34. PubMed ID: 3190993
[TBL] [Abstract][Full Text] [Related]
2. Plasma oxipurinol concentrations during allopurinol therapy.
Emmerson BT; Gordon RB; Cross M; Thomson DB
Br J Rheumatol; 1987 Dec; 26(6):445-9. PubMed ID: 3690140
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
Turnheim K; Krivanek P; Oberbauer R
Br J Clin Pharmacol; 1999 Oct; 48(4):501-9. PubMed ID: 10583019
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects.
Graham S; Day RO; Wong H; McLachlan AJ; Bergendal L; Miners JO; Birkett DJ
Br J Clin Pharmacol; 1996 Apr; 41(4):299-304. PubMed ID: 8730975
[TBL] [Abstract][Full Text] [Related]
5. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.
Day RO; Miners JO; Birkett DJ; Whitehead A; Naidoo D; Hayes J; Savdie E
Br J Clin Pharmacol; 1988 Oct; 26(4):423-8. PubMed ID: 3190992
[TBL] [Abstract][Full Text] [Related]
6. Allopurinol metabolism in a patient with xanthine oxidase deficiency.
Yamanaka H; Nishioka K; Suzuki T; Kohno K
Ann Rheum Dis; 1983 Dec; 42(6):684-6. PubMed ID: 6689118
[TBL] [Abstract][Full Text] [Related]
7. [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
Walter-Sack I; Gröbner W; Zöllner N
Arzneimittelforschung; 1979; 29(5):839-42. PubMed ID: 582985
[TBL] [Abstract][Full Text] [Related]
8. Oxipurinol: alloxanthine, Oxyprim, oxypurinol.
Drugs R D; 2004; 5(3):171-5. PubMed ID: 15139781
[TBL] [Abstract][Full Text] [Related]
9. Demonstration of a combined deficiency of xanthine oxidase and aldehyde oxidase in xanthinuric patients not forming oxipurinol.
Reiter S; Simmonds HA; Zöllner N; Braun SL; Knedel M
Clin Chim Acta; 1990 Mar; 187(3):221-34. PubMed ID: 2323062
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic inhibition assay for fluorometric determination of allopurinol and oxipurinol in serum and urine.
Neubert P; Besenfelder E; Koch K
Arzneimittelforschung; 1980; 30(11):1857-9. PubMed ID: 6893932
[TBL] [Abstract][Full Text] [Related]
11. A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection.
Reinders MK; Nijdam LC; van Roon EN; Movig KL; Jansen TL; van de Laar MA; Brouwers JR
J Pharm Biomed Anal; 2007 Oct; 45(2):312-7. PubMed ID: 17890037
[TBL] [Abstract][Full Text] [Related]
12. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals.
Walter-Sack I; de Vries JX; Kutschker C; Ittensohn A; Voss A
Eur J Clin Pharmacol; 1995; 49(3):215-20. PubMed ID: 8665998
[TBL] [Abstract][Full Text] [Related]
13. [The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
Fenner H; Schiemann O; Gikalov I
Arzneimittelforschung; 1985; 35(7):1093-6. PubMed ID: 4052144
[TBL] [Abstract][Full Text] [Related]
14. Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical.
Spector T
Biochem Pharmacol; 1988 Jan; 37(2):349-52. PubMed ID: 2829916
[TBL] [Abstract][Full Text] [Related]
15. [The influence of allopurinol on purine- and pyrimidinesynthesis (author's transl)].
Gröbner W; Zöllner N
Klin Wochenschr; 1978 Mar; 53(16):255-60. PubMed ID: 682520
[TBL] [Abstract][Full Text] [Related]
16. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol.
Walter-Sack I; de Vries JX; Ernst B; Frei M; Kolb S; Kosmowski J; Priebe U; Schroder HE; Slotty C; Voss A; Weber A; Wegscheider K
J Rheumatol; 1996 Mar; 23(3):498-501. PubMed ID: 8832991
[TBL] [Abstract][Full Text] [Related]
17. The conversion of 4-hydroxypyrazolo[3,4-d]pyrimidine (allopurinol) into 4,6-dihroxypyrazolo[3,4-d]pyrimidine (Oxipurinol) in vivo in the absence of xanthine-oxen oxidoreductase.
Chalmers RA; Parker R; Simmonds HA; Snedden W; Watts RW
Biochem J; 1969 May; 112(4):527-32. PubMed ID: 5801674
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
[TBL] [Abstract][Full Text] [Related]
19. Human and bovine xanthine oxidases. Inhibition studies with oxipurinol.
Spector T; Hall WW; Krenitsky TA
Biochem Pharmacol; 1986 Sep; 35(18):3109-14. PubMed ID: 3755906
[TBL] [Abstract][Full Text] [Related]
20. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy.
Peterson GM; Boyle RR; Francis HW; Oliver NW; Paterson J; von Witt RJ; Taylor GR
Eur J Clin Pharmacol; 1990; 39(4):419-21. PubMed ID: 2076730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
